A major health hazard: the metabolic syndrome.

The clustering of several metabolic and cardiovascular disease risk factors has been termed the metabolic syndrome. The metabolic syndrome seems to result from a collision between susceptible "thrifty genes" and a society characterized by an increased prevalence of obesity and a sedentary lifestyle. The typical patient is characterized by abdominal obesity, a varying degree of glucose intolerance, dyslipidemia and often hypertension. The components of the metabolic syndrome are associated with insulin resistance, disturbances of coagulation and fibrinolysis, endothelial dysfunction and elevated markers of sub-clinical inflammation. The current review focuses mainly on the new definitions of the syndrome, the results of recent epidemiological studies and the consequences of the metabolic syndrome as an important risk factor for cardiovascular disease, premature death and diabetes. The metabolic syndrome constitutes a major challenge for public health professionals in the field of preventive medicine since more than 40 million U.S. adults seem to be affected by the syndrome. Lifestyle changes could have a profound influence on the syndrome and its development.

[1]  H. Halkin,et al.  Elevated serum uric acid — a facet of hyperinsulinaemia , 1987, Diabetologia.

[2]  G. Marchesini,et al.  Association of nonalcoholic fatty liver disease with insulin resistance. , 1999, The American journal of medicine.

[3]  P W Macfarlane,et al.  Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.

[4]  R N Bergman,et al.  Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study. , 1998, JAMA.

[5]  R N Bergman,et al.  Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors. , 1997, American journal of epidemiology.

[6]  Wulf Palinsk.  New Evidence for Beneficial Effects of Statins Unrelated to Lipid Lowering , 2001 .

[7]  L. Niskanen,et al.  Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study. , 2001, American journal of obstetrics and gynecology.

[8]  S. Haffner,et al.  Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. , 1998, Diabetes.

[9]  Robert L Hanson,et al.  Components of the "metabolic syndrome" and incidence of type 2 diabetes. , 2002, Diabetes.

[10]  D. Goff,et al.  Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. , 2000, The American journal of psychiatry.

[11]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.

[12]  P. Zimmet.  Addressing the insulin resistance syndrome: a role for the thiazolidinediones. , 2002, Trends in cardiovascular medicine.

[13]  K. Silver,et al.  Genetics of insulin resistance , 2002, Current diabetes reports.

[14]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[15]  H. Yki-Järvinen,et al.  Hyperuricemia and insulin resistance. , 1994, The Journal of clinical endocrinology and metabolism.

[16]  E. Ford,et al.  A comparison of the prevalence of the metabolic syndrome using two proposed definitions. , 2003, Diabetes care.

[17]  J. Thakore,et al.  Physical consequences of schizophrenia and its treatment: the metabolic syndrome. , 2002, Life sciences.

[18]  P. Angulo,et al.  Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.

[19]  A. Faggiotto,et al.  State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. , 1999, Hypertension.

[20]  Fatty liver—an additional and treatable feature of the insulin resistance syndrome , 1999 .

[21]  A. Folsom,et al.  Multiple Metabolic Syndrome Is Associated With Lower Heart Rate Variability: The Atherosclerosis Risk in Communities Study , 1998, Diabetes Care.

[22]  H. Snieder,et al.  Dissecting the Genetic Architecture of Lipids, Lipoproteins, and Apolipoproteins Lessons from Twin Studies Developmental Trends Trends in Means Brief Reviews , 2022 .

[23]  L. Groop,et al.  Heritability of albumin excretion rate in families of patients with Type II diabetes , 1999, Diabetologia.

[24]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[25]  E. Ernst,et al.  Fibrinogen as a Cardiovascular Risk Factor , 1993, Annals of Internal Medicine.

[26]  M. Taskinen,et al.  Endothelial dysfunction in men with small LDL particles. , 2000, Circulation.

[27]  P. Czernichow,et al.  Insulin resistance early in adulthood in subjects born with intrauterine growth retardation. , 2000, The Journal of clinical endocrinology and metabolism.

[28]  M. Trevisan,et al.  Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. , 1998, American journal of epidemiology.

[29]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[30]  L. Groop,et al.  Metabolic Consequences of a Family History of NIDDM (The Botnia Study): Evidence for Sex-Specific Parental Effects , 1996, Diabetes.

[31]  S. Kiechl,et al.  Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. , 1998, Diabetes.

[32]  B. Balkau,et al.  Comment on the provisional report from the WHO consultation , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[33]  N. Sattar,et al.  Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. , 2002, Diabetes care.

[34]  L. Groop,et al.  Insulin resistance, hypertension and microalbuminuria in patients with Type 2 (non-insulin-dependent) diabetes mellitus , 1993, Diabetologia.

[35]  J. Neel.  Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? , 1962, American journal of human genetics.

[36]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[37]  S. Thompson,et al.  Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[38]  W C Willett,et al.  Low-density lipoprotein subclass patterns and risk of myocardial infarction. , 1988, JAMA.

[39]  M. Hanefeld,et al.  Das Metabolische Syndrom , 2006 .

[40]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[41]  Gerald M. Reaven,et al.  Insulin Resistance: the Metabolic Syndrome X , 2000, European Journal of Clinical Nutrition.

[42]  B. Fagerberg,et al.  The Metabolic Syndrome, LDL Particle Size, and Atherosclerosis: The Atherosclerosis and Insulin Resistance (AIR) Study , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[43]  G. Dagenais,et al.  Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. , 1997, Circulation.

[44]  E. Bruckert,et al.  Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. , 1998, European heart journal.

[45]  P. Wahl,et al.  Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. , 2000, American journal of epidemiology.

[46]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[47]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[48]  G. Reaven,et al.  Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. , 1996, The New England journal of medicine.

[49]  Dm Berwick,et al.  SURGEON GENERAL'S REPORT ON PHYSICAL ACTIVITY AND HEALTH. , 1996 .

[50]  J. Meigs,et al.  Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. , 2000, American journal of epidemiology.

[51]  K. Lindor,et al.  Non‐alcoholic fatty liver disease , 2002, Journal of gastroenterology and hepatology.

[52]  A. Rantala,et al.  Prevalence of the metabolic syndrome in drug‐treated hypertensive patients and control subjects , 1999, Journal of internal medicine.

[53]  M. Laakso,et al.  Hyperinsulinemia cluster predicts the development of type 2 diabetes independently of family history of diabetes. , 1999, Diabetes care.

[54]  C Osmond,et al.  Fetal and infant growth and impaired glucose tolerance at age 64. , 1991, BMJ.

[55]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[56]  D. Gaudet,et al.  Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? , 2000, Circulation.

[57]  M. Whaley,et al.  Physical fitness and clustering of risk factors associated with the metabolic syndrome. , 1999, Medicine and science in sports and exercise.

[58]  A. Döring,et al.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.

[59]  H. Yki-Järvinen,et al.  Endothelial dysfunction in human diabetes , 2002, Current diabetes reports.

[60]  R. Krauss,et al.  Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. , 1996, JAMA.

[61]  A. Dunaif,et al.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. , 1997, Endocrine reviews.

[62]  P. Björntorp,et al.  The metabolic syndrome — a neuroendocrine disorder? , 2000, British Journal of Nutrition.

[63]  R. Krauss,et al.  A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. , 1996, JAMA.

[64]  A Mari,et al.  How to measure insulin sensitivity , 1998, Journal of hypertension.

[65]  Rainer Rauramaa,et al.  Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. , 2002, Diabetes care.

[66]  H. Gerstein,et al.  The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. , 1997, Archives of internal medicine.

[67]  H. Meltzer,et al.  Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. , 2001, The Journal of clinical psychiatry.

[68]  Daniel Steinberg,et al.  Low Density Lipoprotein Oxidation and Its Pathobiological Significance* , 1997, The Journal of Biological Chemistry.

[69]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[70]  M. Laakso,et al.  Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. , 1998, Circulation.

[71]  B. Duncan,et al.  Chronic activation of the innate immune system may underlie the metabolic syndrome , 2001, Sao Paulo medical journal = Revista paulista de medicina.

[72]  M. White,et al.  Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. , 1999, The Journal of clinical investigation.

[73]  L. Groop,et al.  The dysmetabolic syndrome , 2001, Journal of internal medicine.

[74]  A. Hattersley,et al.  The fetal insulin hypothesis: an alternative explanation of the association of low bir thweight with diabetes and vascular disease , 1999, The Lancet.

[75]  M. Stern,et al.  Birthweight and adult health outcomes in a biethnic population in the USA , 1994, Diabetologia.

[76]  B. Howard,et al.  A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects , 1995, Diabetologia.

[77]  M. Neale,et al.  Genetic and Environmental Factors in Relative Body Weight and Human Adiposity , 1997, Behavior genetics.

[78]  Anita L. DeStefano,et al.  Evidence for a Gene Influencing Blood Pressure on Chromosome 17: Genome Scan Linkage Results for Longitudinal Blood Pressure Phenotypes in Subjects From the Framingham Heart Study , 2000, Hypertension.

[79]  K. Borch-Johnsen,et al.  Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. , 1995, Clinical science.

[80]  J. Shaw,et al.  Global and societal implications of the diabetes epidemic , 2001, Nature.

[81]  D. Matthews,et al.  The assessment of insulin resistance in man , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[82]  G. Reaven.  Metabolic Syndrome: Pathophysiology and Implications for Management of Cardiovascular Disease , 2002, Circulation.

[83]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[84]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[85]  J. Ivy.  Role of Exercise Training in the Prevention and Treatment of Insulin Resistance and Non-Insulin-Dependent Diabetes Mellitus , 1997, Sports medicine.

[86]  J. Tooke,et al.  Adverse endothelial function and the insulin resistance syndrome , 2000, Journal of internal medicine.

[87]  C Osmond,et al.  Catch-up growth in childhood and death from coronary heart disease: longitudinal study , 1999, BMJ.

[88]  C. Osmond,et al.  Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth , 2004, Diabetologia.

[89]  J. Ruidavets,et al.  Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. , 2002, Diabetes care.

[90]  S. Jacob,et al.  Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. , 2000, Circulation.

[91]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[92]  S A Stansfeld,et al.  Adrenocortical, Autonomic, and Inflammatory Causes of the Metabolic Syndrome: Nested Case-Control Study , 2002, Circulation.

[93]  K. Schenck-Gustafsson,et al.  Education and the metabolic syndrome in women. , 1999, Diabetes care.

[94]  Paul Hjemdahl.  Stress and the metabolic syndrome: an interesting but enigmatic association. , 2002, Circulation.

[95]  D. Strachan,et al.  C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study , 1996, BMJ.

[96]  J. Hokanson,et al.  Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.

[97]  T. Welborn,et al.  Coronary Heart Disease Incidence and Cardiovascular Mortality in Busselton with Reference to Glucose and Insulin Concentrations , 1979, Diabetes Care.

[98]  N. Kaplan.  The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. , 1989, Archives of internal medicine.

[99]  B. Mitchell,et al.  Genetics of Insulin Resistance , 1999 .